Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary

Annals of Oncology

Volumn 21, Issue 10, 2010, Pages 2075-2080

  Chuang, E ^a   Wiener, N ^a   Christos, P ^a   Kessler, R ^a   Cobham, M ^a   Donovan, D ^a   Goldberg, G L ^b   Caputo, T ^a   Doyle, A ^c   Vahdat, L ^a   Sparano, J A ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Ixabepilone; Liposomal doxorubicin; Ovarian cancer

Indexed keywords

DIPHENHYDRAMINE; DOXORUBICIN; IXABEPILONE; RANITIDINE;

ADULT; AGED; ANOREXIA; ARTICLE; ASTHENIA; BLEEDING; BLOOD TOXICITY; BRAIN ISCHEMIA; BREAST ADENOCARCINOMA; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEPRESSION; DESQUAMATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEARTBURN; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERBILIRUBINEMIA; HYPERPIGMENTATION; INFECTION; LETHARGY; LEUKOCYTE COUNT; LUNG HEMORRHAGE; MAGNESIUM BLOOD LEVEL; MALAISE; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; NEUTROPHILIA; OVARY ADENOCARCINOMA; OVERALL SURVIVAL; PAIN; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; DOXORUBICIN; EPOTHILONES; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 77957148050     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq080     Document Type: Article

References (27)

1. Bollag DM, McQueney PA, Zhu J et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995; 55: 2325-2333.
2. Nicolaou KC, Winssinger N, Pastor J et al. Synthesis of epothilones A and B in solid and solution phase. Nature 1997; 387: 268-272.
3. Hunt JT. Discovery of ixabepilone. Mol Cancer Ther 2009; 8: 275-281.
4. Thomas ES. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2008; 26: 2223.
5. Sparano JA, Vrdoljak E, Rixe O et al. Randomized phase III trial of ixabepilone plus capecitabine vs capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2010; in press.
6. Perez EA, Lerzo G, Pivot X et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007; 25: 3407-3414.
7. Moen MD. Ixabepilone: in locally advanced or metastatic breast cancer. Drugs 2009; 69: 1471-1481.
8. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006; 24: 1633-1642.
9. O'Connor OA, Portlock C, Moskowitz C et al. A multicentre phase II clinical experience with the novel aza-epothilone ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol 2008; 143: 201-209.
10. Zhuang SH, Agrawal M, Edgerly M et al. A phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer 2005; 103: 1932-1938.
11. Low JA, Wedam SB, Lee JJ et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005; 23: 2726-2734.
12. Denduluri N, Low JA, Lee JJ et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007; 25: 3421-3427.
13. Mani S, McDaid H, Hamilton A et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 2004; 10: 1289-1298.
14. Jones L, Hawkins N, Westwood M et al. Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer. Health Technol Assess 2004; 8: 1-143, iii, xiii-xvi.
15. Cianfrocca M, Gradishar WJ. Counterpoint: the argument for combination chemotherapy in the treatment of metastatic breast cancer. J Natl Compr Canc Netw 2007; 5: 673-675.
16. O'Brien ME. Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer. Anticancer Drugs 2008; 19: 1-7.
17. Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312-3322.
18. Gordon AN, Tonda M, Sun S et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2001; 95: 1-8.
19. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
20. Sparano JA, Makhson AN, Semiglazov VF et al. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study. J Clin Oncol 2009; 27: 4522-4529.
21. Trudeau ME, Clemons MJ, Provencher L et al. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines. J Clin Oncol 2009; 27: 5906-5910.
22. Burtness BA, Manola J, Axelrod R et al. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Ann Oncol 2008; 19: 977-983.
23. Lyass O, Uziely B, Ben-Yosef R et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000; 89: 1037-1047.
24. Briasoulis E, Karavasilis V, Tzamakou E et al. Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel. Cancer Chemother Pharmacol 2004; 53: 452-457.
25. Gianni L, Vigano L, Locatelli A et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 1997; 15: 1906-1915.
26. Ferrandina G, Ludovisi M, Lorusso D et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 2008; 26: 890-896.
27. O'Brien ME, Wigler N, Inbar M et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15: 440-499.